RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Enzalutamide Plus Radiation Therapy for High-Risk Localized Prostate Cancer
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 36
SP 18
OP 18
DO 10.1177/155989771436014
UL http://mdc.sagepub.com/content/14/36/18.1.abstract
AB Adjuvant androgen deprivation therapy (ADT), including a luteinizing hormone-releasing hormone analogue (LHRHA) for 2 to 3 years, is the standard of care before, during, and after radiotherapy for patients with localized prostate cancer at high risk of recurrence. However, the optimal regimen remains unclear. This article discusses the phase 3 trial of Enzalutamide in Androgen Deprivation Therapy with Radiation Therapy for High Risk, Clinically Localized, Prostate Cancer [ENZARAD; Australian New Zealand Clinical Trials Registry ACTRN12614000126617]